Fluzoparib+Paclitaxel + Epirubicin+Cyclophosphamide
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
TNBC - Triple-Negative Breast Cancer
Conditions
TNBC - Triple-Negative Breast Cancer
Trial Timeline
Apr 8, 2023 → Jun 1, 2026
NCT ID
NCT05834582About Fluzoparib+Paclitaxel + Epirubicin+Cyclophosphamide
Fluzoparib+Paclitaxel + Epirubicin+Cyclophosphamide is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for TNBC - Triple-Negative Breast Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05834582. Target conditions include TNBC - Triple-Negative Breast Cancer.
What happened to similar drugs?
0 of 2 similar drugs in TNBC - Triple-Negative Breast Cancer were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05834582 | Phase 2 | Recruiting |
Competing Products
14 competing products in TNBC - Triple-Negative Breast Cancer